Evelo Biosciences, Inc. Stock
Evelo Biosciences, Inc. Stock price
Key metrics
Is Evelo Biosciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 7,018 stocks worldwide.
Evelo Biosciences, Inc. Stock Analysis
Analyst Opinions
7 Analysts have issued a Evelo Biosciences, Inc. forecast:
Analyst Opinions
7 Analysts have issued a Evelo Biosciences, Inc. forecast:
Financial data from Evelo Biosciences, Inc.
| Sep '23 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -73 -73 |
36%
36%
|
EBIT (Operating Income) EBIT | -74 -74 |
35%
35%
|
| Net Profit | -82 -82 |
31%
31%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Evelo Biosciences, Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
Evelo Biosciences, Inc. operates as a clinical stage biotechnology company. The firm engages in the development of monoclonal microbials, a modality of oral biologic medicines. It has three product candidates, EDP1066 and EDP1815 for the treatment of inflammatory diseases and EDP1503 for the treatment of cancer. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Cambridge, MA.
| Head office | United States |
| CEO | Craig Jalbert |
| Employees | 66 |
| Founded | 2014 |
| Website | evelobio.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
